2021
Thought Leadership Webinar Series
This live webinar with Roche took place on
March 18th, 2020
11am EDT / 3pm GMT / 4pm CET
Unfortunately there is no recording available.
Markus Haindl, Roche: in vivo gene therapy - Applications and future needs for proteomic tools
PreOmics is happy to kick off the Thought Leadership Webinar Series 2021 with our visionary guest speakers Markus Haindl from Roche and Philipp E. Geyer from our partner company OmicEra Diagnostics. Markus' talk is titled "in vivo gene therapy - Application and future needs for proteomic tools".
Abstract:
Proteomics is evolving into an increasingly versatile set of tools to explore the poorly characterized field of ATMPs (Advanced Therapy Medicinal Products). Delivery of in vivo gene therapies - probably the most prominent example in the group of ATMPs - are currently essentially based on viral vectors. These are highly complex biomolecules consisting of a capsid, an ensemble of a multitude of protein subunits, and a payload, a nucleic acid of several kb in length which is carrying the genetic information transmitted to the patient cell's nucleus. Both the manufacturing and the mode of action of these therapies are highly complex and not well characterized. Proteomic tools are very powerful for better understanding the basic biologic processes in manufacturing as well as in vivo to connect quality attributes of these biomolecules to clinical outcomes.
Markus will focus on the immediate needs and look to the future, giving his vision of ATMP analyses with specific regard to proteomics.
This is part 1 of our series of webinars from leading-edge researchers giving their proteomic and protein analysis visions for the future.
Agenda and Speakers
March 18, 2021 (11am EDT / 3pm GMT / 4pm CET)
- 5 min - Welcome and intro by Garwin Pichler, PreOmics
- 30 min - Presentation by Markus Haindl: "in vivo gene therapy - Applications and future needs for proteomic tools"
- 5 min - Philipp E. Geyer, OmicEra Diagnostics
- 15 min - Q&A session
Your questions answered by experts:
Markus Haindl - Lead Gene Therapy Technical Development - Roche
Markus finished his PhD in 2008 in Molecular Cell Biology at the Max-Planck-Institute for Biochemistry in Munich. He subsequently joined McKinsey&Company as a consultant, taking over international strategy and operations projects for clients within the Pharma, Biotech and High-Tech industry.
In late 2010 Markus joined Roche at the Biotech Centre in Penzberg, Germany. Since then, he has held positions as a Group leader in Bioprocess Development and Analytical Development, Department Head for Analytical Development & New Technologies before becoming the Lead for Technical Development for in vivo Gene Therapy
Garwin Pichler - Founder and CEO at PreOmics
Garwin is co-founder and CEO here at PreOmics. Garwin holds a PhD in Biochemistry from the LMU Munich (Germany). Garwin joined Nils Kulak working on the iST Technology in the Matthias Mann lab. Together they founded PreOmics in 2016 and Garwin is responsible for Finances, Business Development, Investor Relationship and HR.
Philipp E. Geyer - Co-founder & Managing Director at OmicEra Diagnostics
Philipp Emanuel Geyer is co-founder and CSO at OmicEra Diagnostics. Philipp holds a PhD in Biochemistry from the LMU Munich (Germany). He headed the blood plasma proteomics efforts in Matthias Mann's labs at the Max Planck Institute in Munich and the Center of Protein Research in Copenhagen. He co-authored more than 25 peer-reviewed scientific publications. In 2019, he co-founded OmicEra Diagnostics with Sophia Doll and Sebastian Virreira Winter.
Copyright ©2020 All Rights Reserved
PreOmics GmbH
Am Klopferspitz 19
D-82152 Planegg/Martinsried
Phone: +49-89-2314163-0
Fax: +49-89-2314163-99
E-mail: info@preomics.com